Ketones

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Retrieved on: 
Thursday, April 29, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, United States patent law, Pain management, Patent

b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.

Key Points: 
  • b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.
  • 10,973,780, describing pharmaceutical formulations and treatment methods including the company\'s BB106 ketamine therapy.
  • This patent represents Bexson\'s first application of these innovations to enable a subcutaneous ketamine delivery platform designed for management of pain disorders and mental health conditions.
  • The patent process is a long road and we are pleased to see this first one be issued," said Gregg Peterson, Bexson co-founder and CEO.\nThe company is engaging FDA to prepare for clinical trials evaluating its patented ketamine formula delivered subcutaneously.

Athenex, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Retrieved on: 
Thursday, April 29, 2021
Carbonyl compounds, Drugs, Oxygen compounds, Bristol-Myers Squibb, Ketones, Paclitaxel, Taxanes, Clinical endpoint

On March 1, 2021, Athenex announced that the FDA had issued a complete response letter for their New Drug Application for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer.

Key Points: 
  • On March 1, 2021, Athenex announced that the FDA had issued a complete response letter for their New Drug Application for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer.
  • The FDA\'s CRL cited patient safety risks, as well as uncertainty in relation to primary endpoint results for the objective response rate ("ORR") which may have introduced bias in the blinded clinical review.
  • Shares of Athenex fell by 55% in one day based on this news.\nA class action lawsuit has already been filed.
  • The Firm\xe2\x80\x99s founding partner has recovered over $5.5 billion for aggrieved investors.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Pharmaceutical, Health, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Ketones, Neurochemistry, Sedatives, Chloroarenes, Anticonvulsants, Ganaxolone, Antidepressant, Ketamine, Allosteric regulation

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.

Key Points: 
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.
  • For more information visit www.marinuspharma.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428006117/en/\n'

Antares Pharma to Participate in the 7th Annual Truist Securities 2021 Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Steroids, Organic compounds, Androstanes, Chemical compounds, Ketones, Testosterone, Testosterone enanthate, XC2, Forward-looking statement, Subcutaneous, Ferring Pharmaceuticals, Sumatriptan

Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

Key Points: 
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • The Company also markets NOCDURNA\xc2\xae (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.\nThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.
  • The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release.

Antares Pharma to Report First Quarter 2021 Financial and Operating Results

Retrieved on: 
Tuesday, April 27, 2021
Drugs, Steroids, Organic compounds, Androstanes, Ketones, Testosterone, XC2, Testosterone enanthate, Subcutaneous, Sumatriptan, Methotrexate, Teva Pharmaceuticals

b'EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (\xe2\x80\x9cthe Company\xe2\x80\x9d), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens.\nAntares\xc2\xa0will host a conference call on\xc2\xa0Thursday, May 6, 2021 at\xc2\xa08:30am ET\xc2\xa0to discuss the results.

Key Points: 
  • b'EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (\xe2\x80\x9cthe Company\xe2\x80\x9d), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens.\nAntares\xc2\xa0will host a conference call on\xc2\xa0Thursday, May 6, 2021 at\xc2\xa08:30am ET\xc2\xa0to discuss the results.
  • The dial-in numbers are (800) 367-2403 for domestic callers and (334) 777-6978 for international callers.
  • Antares Pharma\xe2\x80\x99s FDA-approved products include XYOSTED\xc2\xae (testosterone enanthate) injection, OTREXUP\xc2\xae (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

Retrieved on: 
Thursday, April 22, 2021
Health, Infectious diseases, Surgery, General Health, Pharmaceutical, Biotechnology, Drugs, Clinical medicine, Psychoactive drugs, Euphoriants, Ketones, Analgesics, General anesthetics, Enkephalin, Nasal administration, Ketamine, Chronic pain, Torreya, Virpax Pharmaceuticals, TORREYA, VIRPAX PHARMACEUTICALS

Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.

Key Points: 
  • Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.
  • We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, capital markets, licensing, and asset sale transactions.
  • Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence.
  • Envelta\xe2\x84\xa2 is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Neurosteroids, Sterols, Chemical compounds, Ganaxolone, Chemistry

b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.
  • The stock option was granted as an inducement material to Mr. Pfanstiel entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the award agreement covering such grant.\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex (ATNX) Investors of Securities Fraud Lawsuit and Application Deadline, Encourages Investors with Losses to Contact Their Attorneys

Retrieved on: 
Monday, April 5, 2021
Carbonyl compounds, Oxygen compounds, Branches of biology, Taxanes, Bristol-Myers Squibb, Ketones, Paclitaxel, Steve Berman, Neutropenia, CRL, Hagens

1, 2021, the market learned the truth when Athenex announced it received the FDAs complete response letter (CRL) to the NDA for oral paclitaxel plus encequidar.

Key Points: 
  • 1, 2021, the market learned the truth when Athenex announced it received the FDAs complete response letter (CRL) to the NDA for oral paclitaxel plus encequidar.
  • In the CRL, the FDA cited safety risks to patients in terms of an increase in neutropenia-related sequalae.
  • Were focused on investors losses and proving Athenex intentionally misled investors about its leading drug candidate, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.

Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose

Retrieved on: 
Wednesday, March 31, 2021
Health sciences, Health care, Drugs, Pharmacy, Ketones, Naloxone, Pharmaceutical industry, Food and Drug Administration, Emergent BioSolutions

The grant was awarded under award number 5U01DA046093-03.

Key Points: 
  • The grant was awarded under award number 5U01DA046093-03.
  • The award of the final tranche of NIDAs grant validates the progress we are making to develop OPNT003 for submission to the FDA, saidRoger Crystal, M.D., President and CEO, Opiant Pharmaceuticals.
  • Further details are available at:
    In addition to the grant from NIDA, the development of OPNT003 is supported by a contract with theBiological Advance Research and Development Agency.
  • Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leadingfranchiseof new medicines to combat addictions and drug overdose.

American Society of Ketamine Physicians, Psychotherapists and Practitioners Recommends the Ethical Prescription and Administration of Ketamine

Retrieved on: 
Friday, March 12, 2021
Drugs, Psychoactive drugs, Neurochemistry, Amines, Chloroarenes, Ketones, Nicotinic antagonists, Sedatives, Ketamine

One such example includes the unethical prescription and administration of IV ketamine in a home or even hotel room without an in-person evaluation by the prescribing provider.

Key Points: 
  • One such example includes the unethical prescription and administration of IV ketamine in a home or even hotel room without an in-person evaluation by the prescribing provider.
  • Their purpose is to serve as guidelines for safe and ethical administration of ketamine in practice.
  • (American Society of Ketamine Physicians, Psychotherapists, and Practitioners) In addition, ASKP3 composed a comprehensive Ethics Statement for ketamine providers in 2020 that is currently pending publication.
  • ASKP3: American Society of Ketamine Physicians, Psychotherapists, and Practitioners, 2020, ASKP3 Standards - ASKP.